Abstract. The effect of 7 months treatment with subcutaneous insulin-like growth factor-I (IGF-I ) in a 6 year old boy with normal growth hormone secretion and low serum IGF-I was studied. The initial dose of biosynthetic IGF-I was 0.05mg/kg/day and it was increased to 0.2mg/kg/day. The patient's annualized height velocity was 9.3cm/year during IGF-I treatment compared to 5.0cm/year before treatment. There were no significant changes in biochemical measurements except for the level of IGF-I during treatment. This suggests that the patient's short stature might have been related to the low concentration of IGF-I.
Introduction
The efficacy of treatment with biosynthetic insulin-like growth factor-I (IGF-I ) in children with the GH insensitivity syndrome has been the subject of recent reports [1, 2, 3] . Children with the GH insensitivity syndrome have severe growth retardation and low levels of serum IGF-I [4, 5] . This syndrome results from the inability of GH to generate IGF-I [5, 6] . In this study we used biosynthetic IGF-I in a boy with growth retardation and a low serum concentration of IGF-I, for 7 months, and evaluated its effect.
Case Report
The patient was 6 year old boy, the third child of healty parents. The father's height was 177cm and the mother's 150cm. The brother's height was 170cm at 15y and the sister's 150cm at lly. The patient was born at 39 weeks gestation weighing 2,740g. The short stature was first noted at 4 months ( -2.5SD). Mild hypothyroidism was found at 3y9m (T4: 5.3y g/dl, T3: 0.6ng/ml, TSH: 2.31Wimp. He was treated with L-thyroxine which did not change his rate of growth. The GH provocation test revealed normal GH secretion under normal thyroid function at 4y9m (Table 1) . A trial of GH injections for 3.5 months had also no effect on his growth velocity (Fig. 1) . Serum levels of IGF-I remained low during GH injections (Fig. 2) . We considered his short When the patient enrolled in this study at 6y9m of age, his height was 103.5cm ( -2.9SD) and weight was 16.2kg ( -1.8SD). Laboratory data on admission is shown in Table 2 . His bone age was 3.7 years (TW II method). Informed consent was obtained from the patient and his parents. The patient was observed without treatment for 6 days and then received subcutaneous injections of rhGH (41U/day) on days 7, 9, 11. After base-line studies, biosynthetic IGF-I (gift of Fujisawa Pharmaceutical, Osaka, Japan) was injected subcutaneously twice daily on days 15 through 26. The injections were given immediately before breakfast and before dinner. The initial dose was 0.05mg/kg/day and it was increased to 0.2mg/kg/day. Serum samples were obtained every 2-3 days. Daily 24-hour urine samples were collected throughout the hospitalization. After discharge from hospital IGF-I was administrated for 6 months at home. Because the injections were painful, the IGF-I treatment was changed to an injection once daily 2.5 months after the beginning of the treatment. Serial height measurements and serum samples were obtained at 2-8 week intervals. The treatment ended at 7y4m.
Results
Effect on linear growth (Fig.1) The patient's annualized height velocity was 5.0cm/year ( -1.0SD for chronological age) before IGF-I treatment.
During IGF-I treatment, the patient's height increased from 103.5cm ( -2.9SD) to 108.9cm ( -2.5SD) in 7 months, an annualized height velocity of 9.3cm/year ( +4.3SD for chronological age). After IGF-I treatment, the patient's height increased from 108.9cm (-2.5SD) to 111.4cm (-2.5SD) in 4 months, an annualized height velocity of 7.5cm/year ( +2.1SD for chronological age). Bone age after 7 months of therapy was 4.0 years.
Effect on serum measurements (Fig.3,4 ) The administration of GH was not associated with significant biochemical changes except for the level of ketone bodies which was increased, reflecting lipolysis by GH. IGF-I given subcutaneously increased the serum concentration of IGF-I significantly (Fig.5) . The fasting levels of urea nitrogen and insulin were reduced and the levels of ALP were increased. However, these changes were not significant.
Fasting blood levels of glucose, calcium, phosphate, total ketone bodies and IGF-BP3 were not changed significantly during IGF-I treatment.
After treatment, the serum IGF-I returned to the same level as before treatment.
Discussion
This patient had short stature ( -2.9SD), retardation of bone age (3 years behind chronological age), low serum IGF-I, and normal GH secretion. These characteristics let us to consider that his short stature might be related to the low concentration of IGF-I from insuffient IGF-I production, which is commonly found in children with Laron dwarfism (GH insensitivity syndrome) [4, 5] . Because GH-BP was not measured, it could not be confirmed that this patient had Larontype dwarfism.
Considering the significantly increased annualized rate of growth of 9.3cm/year during treatment, the IGF-I seemed to be effective in this case. His annualized height velocity of 7.5cm/year after the treatment was also higher than before treatment, although the reason for this was unclear.
In this study we examined the anabolic and metabolic responses to IGF-I treatment. However, he was too young to collect daily 24 hour urine consistently, so reliable data for 24-hour urinary excretion of urea nitrogen, calcium, phosphate, sodium and other biochemical measurements were not obtained.
A reduction in serum urea nitrogen in a child with growth hormone insensitivity syndrome (Laron dwarfism) has been reported [1, 3] 
